Firm’s therapeutic dendritic cell-based vaccine know-how goals to supply new therapy choices for youngsters with recurring metastatic Ewing sarcoma and osteosarcoma
LOS ANGELES, June 20, 2024–(BUSINESS WIRE)–CellxLife right this moment introduced that Eric von Hofe, Ph.D., will function the corporate’s first Chief Govt Officer. The corporate was fashioned in late 2023 to advance a dendritic cell-based therapeutic vaccine candidate that goals to develop therapy choices for youngsters with recurring metastatic Ewing sarcoma and osteosarcoma.
There are presently only a few therapy choices for youngsters affected by metastatic Ewing sarcoma or osteosarcoma. The commonest therapy is surgical removing of the tumors together with radiation and chemotherapy. For youngsters with recurring metastatic Ewing sarcoma or osteosarcoma, the 5-year survival price is often 20-30% and within the U.S., roughly $750,000 is spent on therapy over the course of a affected person’s life. i,ii
“Ewing sarcoma and osteosarcoma are devastating ailments which have far-reaching affect, notably in pediatric sufferers and their caregivers,” stated Dr. von Hofe. “I’m honored to affix the CellxLife staff to assist advance efforts in bringing this promising new biotherapeutic to the hundreds of kids and households combating these cancers globally.”
By means of CellxLife’s proprietary platform, dendritic cells are taken from the physique and offered with the affected person’s personal tumor cell antigens, then re-administered again into the physique as an immunotherapeutic vaccine to coach the immune system. Research information generated so far has indicated that this each prompts immune cells to assault remaining most cancers cells within the physique and shapes the immunological reminiscence to drastically scale back the possibilities of most cancers recurrence. In a previous Section 1 research, 75% of pediatric individuals recognized with metastatic Ewing’s or osteosarcoma, who responded properly to surgical procedure, overcame their most cancers, and are nonetheless alive right this moment. Out of all of the individuals within the trial, 62.5% of kids with metastatic osteosarcoma who had been handled with the dendritic cell-based remedy lived for greater than 15 years.
The CellxLife scientific staff believes the remedy can cross over to different stable tumors, akin to ovarian, breast, colorectal, pancreatic, glioblastoma, lung, and different stable tumors. The precept is similar; as soon as a tumor is eliminated, the vaccine will form the immunological reminiscence of the most cancers cells within the lymph nodes and drastically scale back the possibilities of most cancers recurrence.
“This could possibly be a breakthrough for anybody who’s confronted with the horrible realization that most cancers might reoccur after their tumor is eliminated,” stated Ruvin Orbach, founding father of CellxLife. “It’s an honor to have Eric on board as CEO at this essential time of development for CellxLife. We’re dedicated to constructing the staff and elevating the capital required to additional advance this de-risked therapeutic candidate. We’re presently planning the Section II trials with an orphan designation and considerably decreasing the regulatory pathway for this promising immunotherapy.”
Dr. von Hofe has over 30 years of expertise in managing and overseeing biotechnology applications, with a give attention to most cancers immunotherapy and know-how improvement. Most lately he led improvement efforts at AffyImmune Therapeutics the place he oversaw the scientific improvement and orphan designation for a novel CAR-T cell therapeutic focusing on refractory thyroid most cancers. Beforehand, he was at Antigen Specific the place he led the event of an immunotherapeutic vaccine for breast and prostate most cancers, leading to a collaboration with Merck. Previous to that, he labored at Millennium Prescription drugs first as Program Director for Goal Validation and later as Director of Applications & Operations, Discovery Analysis. Beforehand, Dr. von Hofe was Director, New Targets at Hybridon, Inc., the place he coordinated in-house and collaborative analysis that validated gene targets for novel antisense medicines. Dr. von Hofe additionally held the place of Assistant Professor of Pharmacology on the College of Massachusetts Medical Faculty, the place he obtained a Nationwide Most cancers Institute Profession Growth Award for outlining mechanisms by which alkylating carcinogens create cancers. He obtained his Ph.D. in Experimental Pathology from the College of Southern California and was a postdoctoral fellow at each the College of Zurich and Harvard College Faculty of Public Well being.
For extra info, please go to www.cellxlife.com.
About CellxLife
CellxLife is a Section I/II-stage biotechnology firm based in 2023 to accumulate promising biotherapies and speed up their regulatory approval. The corporate’s preliminary program is concentrated on advancing a dendritic cell-derived vaccine remedy focusing on metastatic Ewing sarcoma and osteosarcoma. The corporate can also be presently planning a basket trial for 5 different stable tumor indications. Primarily based in Los Angeles, California, CellxLife may be discovered on-line at www.cellxlife.com.
____________________
i https://www.dana-farber.org/cancer-care/sorts/childhood-ewing-sarcoma#:~:textual content=Thepercent20fivepercent2Dyearpercent20survivalpercent20rate,ispercent2020percent20topercent2030percent20percent
ii https://pubmed.ncbi.nlm.nih.gov/30255612/
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240620077018/en/
Contacts
Ruvin Orbach
ruvin@cellxlife.com